Electronic Nicotine Delivery SystemsEXERVAPENCT06474962
Cardiorespiratory Fitness and Health Parameters in E-cigarrete Users: Impact of a Short Term Pause in Consumption
A study testing Pause in people with Electronic Nicotine Delivery Systems, run by University of Sao Paulo at 1 site in Brazil.
Trial summary
Goal: Investigate the health effects of electronic cigarettes (e-cigarettes) and whether a short break from using them can improve health. Participants: Up to 148 people (74 who use e-cigarettes and 74 who don't) Age and sex will be matched between the groups. Read more about this study
- Who is it for?
- Ages 14 years and olderHealthy volunteers can take part
- Conditions the study is for
- Electronic Nicotine Delivery Systems
- What is being tested?
- Pause
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 148 participants
- Where
- 1 siteBrazil
- Study dates
- Jun 2024to Apr 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 14 years and older
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- 14 years of age or older
- Reporting using nicotine electronic cigarettes (e-cigarettes)
- Serum cotinine levels equal to or greater than 3 ng/mL
Who cannot join
- Contraindications for maximum exercise testing or any of study procedures
- Use of any smoking product except e-cigarette (combustible cigarette, cigar, hookah, marijuana, etc.)
Trial locations and contacts
1 site in 1 country.
Brazil1 site
Clinical Hospital of the School of Medicine, University of Sao Paulo
São Paulo, 05403-000
About this study
Goal: Investigate the health effects of electronic cigarettes (e-cigarettes) and whether a short break from using them can improve health.
Participants:
Read more
Up to 148 people (74 who use e-cigarettes and 74 who don't) Age and sex will be matched between the groups.
Study Design:
Two connected studies:
Observational Study: Compares general health (including lung function, heart health, blood pressure, and inflammation) of e-cigarette users to non-smokers.
Clinical Trial: E-cigarette users will be randomly assigned to either:
Take a 7-day break from e-cigarettes (intervention group) Continue using e-cigarettes as usual (control group) Both groups will have their health measured before and after the 7-day period. Main Outcome: How well your heart and lungs work during exercise.
Other Outcomes: Lung function, blood vessel function, risk factors for heart disease, and body measurements.
Why is this study important?
E-cigarettes are becoming more popular, but their health effects are unknown. This study will provide new information on whether e-cigarettes harm your health and if quitting for a short time can improve it.
This information can be used to create better public health policies about e-cigarettes.
Read the detailed description
The emergence of electronic smoking devices is a recent and scientifically underexplored phenomenon. These devices were initially thought of as a harm-reduction strategy in cigarette smokers, a purpose for which there is still no definitive evidence of effectiveness. Preliminary but consistent findings in the literature suggest the possibility of detrimental health effects to e-cigarette users. Despite being prohibited for sale in the country, electronic cigarettes are easily accessible, in an unregulated manner. The increasing number of users, approaching one million according to recent data, and the uncertainties regarding the composition, manufacturing quality, and potential long-term effects of exposure to the vapor they produce, make the use of electronic cigarettes an emerging issue in Brazilian public health. Based on the aforementioned issues, exploring the potential effects of this new health-related behavior is urgent. Thus, the present proposal describes a research project envisioning the execution of two interconnected studies: (1) an observational cross-sectional analysis, in an exposed-control design, evaluating general health parameters of electronic cigarette users compared to non-smoking control individuals, matched by sex and age; and (2) an intervention study nested within the first study, designed as a randomized clinical trial, with electronic cigarette users assigned to a group that will take a 7-day pause from using these devices, compared to a control group that will not undergo any intervention. The studies were designed with cardiorespiratory fitness - measured by a maximum exercise cardiopulmonary test (ergospirometry) - as the primary outcome. The sample size calculated for the cross-sectional study comprises 148 individuals (74 per group), and the intended sample for the randomized clinical trial consists of the 74 electronic cigarette users already recruited for the cross-sectional study. The secondary outcomes of both studies are related to cardiorespiratory parameters, pulmonary function (spirometry), vascular function (endothelial function and tissue oxygenation), cardiovascular risk (lipid profile and blood pressure), inflammatory markers, and anthropometric measurements. The statistical analyses will be performed using Analysis of Covariance (ANCOVA), with physical activity level as a covariate for the cross-sectional study, and Generalized Estimating Equations (GEE), with initial oxygen consumption value as a covariate for the clinical trial. The investigators expect that the proposed studies yield new and relevant information regarding the potential harmful effects of electronic cigarettes, as well as the possibility of reversing these effects through refraining from their consumption. The novelty of the studies, the urgency of the topic, the boldness of the experimental approaches, and the high immediate applicability of the findings are highlighted in this proposal, with the potential to support public health policies concerning this relevant issue.
- Conditions
- Electronic Nicotine Delivery Systems
- Being tested
- Pause
- Keywords
- vaping, e-cigarette
- Medical subject headings
- Vaping
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PauseBehavioural
7 days of no e-cigarette consumption
| Study group | Role | What they receive |
|---|---|---|
| Pause | Experimental | Individuals will attempt to halt e-cigarette consumption for 7 days Receives: Behavioral: Pause |
| Control | No intervention | Individuals will continue habits as usual |
What is being measured
The primary outcome is the main question the study is designed to answer.
Maximal oxygen consumption
Maximal cardiorespiratory fitness assessed in a treadmill test
Measured: Baseline
Maximal oxygen consumption
Maximal cardiorespiratory fitness assessed in a treadmill test
Measured: 7 days
Secondary outcomes (13)
Pulmonary function
Assessed through spirometry analysis of flow volume loops patterns
Measured: Baseline
Pulmonary function
Assessed through spirometry analysis of flow volume loops patterns
Measured: 7 days
Endothelial function
Assessed through ultrasonography of brachial artery
Measured: Baseline
Endothelial function
Assessed through ultrasonography of brachial artery
Measured: 7 days
Lipid profile
Blood concentrations of HDL cholesterol, LDL cholesterol, total cholesterol and tryglicerides
Measured: Baseline
Lipid profile
Blood concentrations of HDL cholesterol, LDL cholesterol, total cholesterol and tryglicerides
Measured: 7 days
Health-related quality of life
Assessed through "Short-form 36" questionnaire
Measured: Baseline
Health-related quality of life
Assessed through "Short-form 36" questionnaire
Measured: 7 days
Anxiety symptoms
Assessed through Beck's Anxiety Inventory
Measured: Baseline
Anxiety symptoms
Assessed through Beck's Anxiety Inventory
Measured: 7 days
Blood pressure
Office blood pressure measured with automated oscillometric device
Measured: Baseline
Inflammatory status
Measured by blood concentration of inflammatory markers: interleukins 6 and 10, interferon-gamma, c-reactive protein and tumoral necrosis factor alpha
Measured: Baseline
Inflammatory status
Measured by blood concentration of inflammatory markers: interleukins 6 and 10, interferon-gamma, c-reactive protein and tumoral necrosis factor alpha
Measured: 7 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Jun 2024
- Study startJun 2024 (estimated)
- Primary completionApr 2026 (estimated)
- Study completionApr 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Electronic Nicotine Delivery SystemsStudies of the same condition, open and under way.
- More trials run by University of Sao PauloThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 148 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Sao Paulo
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Bruno Gualano, University of Sao Paulo
- Investigators
- Bruno Gualano, PhD, Principal investigator, University of Sao Paulo
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06474962
- Sponsor's protocol ID
- 71092523.7.0000.0068
- Acronym
- EXERVAPE
- Status last verified
- Jun 2024
- First submitted
- 4 Jun 2024
- Last updated
- 26 Jun 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Data will be shared in accordance with institutional and legal requirements and will be provided upon reasonable request.
Study at a glance
From the registry record, last updated by the sponsor on 26 Jun 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Cardiorespiratory Fitness and Health Parameters in E-cigarrete Users: Impact of a Short Term Pause in Consumption
- ClinicalTrials.gov ID
- NCT06474962
- Acronym / sponsor ID
- EXERVAPE / 71092523.7.0000.0068
- Conditions
- Electronic Nicotine Delivery Systems
- Keywords
- vaping, e-cigarette
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 148 participants (estimated)
- Lead sponsor
- University of Sao PauloUniversity, hospital or other
- Study start
- Jun 2024 (estimated)
- Primary completion
- Apr 2026 (estimated)
- Study completion
- Apr 2026 (estimated)
- First posted
- 26 Jun 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Goal: Investigate the health effects of electronic cigarettes (e-cigarettes) and whether a short break from using them can improve health.
Participants:
Up to 148 people (74 who use e-cigarettes and 74 who don't) Age and sex will be matched between the groups.
Study Design:
Two connected studies:
Observational Study: Compares general health (including lung function, heart health, blood pressure, and inflammation) of e-cigarette users to non-smokers.
Clinical Trial: E-cigarette users will be randomly assigned to either:
Take a 7-day break from e-cigarettes (intervention group) Continue using e-cigarettes as usual (control group) Both groups will have their health measured before and after the 7-day period. Main Outcome: How well your heart and lungs work during exercise.
Other Outcomes: Lung function, blood vessel function, risk factors for heart disease, and body measurements.
Why is this study important?
E-cigarettes are becoming more popular, but their health effects are unknown. This study will provide new information on whether e-cigarettes harm your health and if quitting for a short time can improve it.
This information can be used to create better public health policies about e-cigarettes.
Detailed description
The emergence of electronic smoking devices is a recent and scientifically underexplored phenomenon. These devices were initially thought of as a harm-reduction strategy in cigarette smokers, a purpose for which there is still no definitive evidence of effectiveness. Preliminary but consistent findings in the literature suggest the possibility of detrimental health effects to e-cigarette users. Despite being prohibited for sale in the country, electronic cigarettes are easily accessible, in an unregulated manner. The increasing number of users, approaching one million according to recent data, and the uncertainties regarding the composition, manufacturing quality, and potential long-term effects of exposure to the vapor they produce, make the use of electronic cigarettes an emerging issue in Brazilian public health. Based on the aforementioned issues, exploring the potential effects of this new health-related behavior is urgent. Thus, the present proposal describes a research project envisioning the execution of two interconnected studies: (1) an observational cross-sectional analysis, in an exposed-control design, evaluating general health parameters of electronic cigarette users compared to non-smoking control individuals, matched by sex and age; and (2) an intervention study nested within the first study, designed as a randomized clinical trial, with electronic cigarette users assigned to a group that will take a 7-day pause from using these devices, compared to a control group that will not undergo any intervention. The studies were designed with cardiorespiratory fitness - measured by a maximum exercise cardiopulmonary test (ergospirometry) - as the primary outcome. The sample size calculated for the cross-sectional study comprises 148 individuals (74 per group), and the intended sample for the randomized clinical trial consists of the 74 electronic cigarette users already recruited for the cross-sectional study. The secondary outcomes of both studies are related to cardiorespiratory parameters, pulmonary function (spirometry), vascular function (endothelial function and tissue oxygenation), cardiovascular risk (lipid profile and blood pressure), inflammatory markers, and anthropometric measurements. The statistical analyses will be performed using Analysis of Covariance (ANCOVA), with physical activity level as a covariate for the cross-sectional study, and Generalized Estimating Equations (GEE), with initial oxygen consumption value as a covariate for the clinical trial. The investigators expect that the proposed studies yield new and relevant information regarding the potential harmful effects of electronic cigarettes, as well as the possibility of reversing these effects through refraining from their consumption. The novelty of the studies, the urgency of the topic, the boldness of the experimental approaches, and the high immediate applicability of the findings are highlighted in this proposal, with the potential to support public health policies concerning this relevant issue.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Pause | Experimental | Behavioral: PauseIndividuals will attempt to halt e-cigarette consumption for 7 days |
| Control | No intervention | –Individuals will continue habits as usual |
Who may qualify
- Ages
- 14 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (3 listed)
- 14 years of age or older
- Reporting using nicotine electronic cigarettes (e-cigarettes)
- Serum cotinine levels equal to or greater than 3 ng/mL
Key exclusion criteria (2 listed)
- Contraindications for maximum exercise testing or any of study procedures
- Use of any smoking product except e-cigarette (combustible cigarette, cigar, hookah, marijuana, etc.)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Pause7 days of no e-cigarette consumption | Behavioural | Pause |
Primary outcome
Maximal oxygen consumption
Time frame: Baseline
Maximal cardiorespiratory fitness assessed in a treadmill test
Maximal oxygen consumption
Time frame: 7 days
Maximal cardiorespiratory fitness assessed in a treadmill test
13 secondary outcomes
Pulmonary function
Time frame: Baseline
Pulmonary function
Time frame: 7 days
Endothelial function
Time frame: Baseline
Endothelial function
Time frame: 7 days
Lipid profile
Time frame: Baseline
Lipid profile
Time frame: 7 days
Health-related quality of life
Time frame: Baseline
Health-related quality of life
Time frame: 7 days
Anxiety symptoms
Time frame: Baseline
Anxiety symptoms
Time frame: 7 days
Blood pressure
Time frame: Baseline
Inflammatory status
Time frame: Baseline
Inflammatory status
Time frame: 7 days
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Jun 2024.
- Individual participant dataSharing planned: Yes. Data will be shared in accordance with institutional and legal requirements and will be provided upon reasonable request.
Related trials for Electronic Nicotine Delivery Systems
Not yet recruiting
Flavored Electronic Nicotine Delivery Systems to Lower Smoking and Exposure to Tobacco Toxicants Among Cigarette Smokers Interested in Quitting, REFLECT Trial
Tobacco Cessation, Electronic Nicotine Delivery Systems
Recruiting
A Study to Determine the Effect of Access to Multiple Tobacco Flavor Options on Smoking Abstinence Among Primary Cigarette Smokers Using an Electronic Nicotine Delivery System
Smoking, Tobacco
Not yet recruiting
A Study to Assess Nicotine Uptake From a Menthol Electronic Nicotine Delivery System Product
Smoking Behaviors, Smoking ( Cigarette)
Not yet recruiting
Survey to Test the Nicotine Concentration and Nicotine Flux Labels for E-cigarettes
Nicotine Labeling for E-cigarettes
Not yet recruiting
A Study to Assess Nicotine Uptake From Electronic Nicotine Delivery System Products
Smoking Behaviors, Smoking ( Cigarette)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Bruno Gualano, PhD principal investigator
University of Sao Paulo
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Pause in people with Electronic Nicotine Delivery Systems, run by University of Sao Paulo at 1 site in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 26 Jun 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Bruno Gualano, PhD (551126618022, gualano@usp.br), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Maximal oxygen consumption (time frame: Baseline). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jun 2024.